In summary, we provide the evidence that endogenous TRAF6 is an essential molecular switch for the development of pathological cardiac hypertrophy, which is dependent on TRAF6 ubiquitination, TRAF6–TAK1 interactions, and the TRAF6-induced ubiquitination of TAK1. Here, TRAF6 is linked to cardiac hypertrophy.